In vitro and in vivo evaluation of WAC-224, a novel quinolone class of topoisomerase II inhibitor for cancer therapy

被引：0
|
作者：
Ueshima, Taichi
Yamaguchi, Tomonori
Itoh, Kenji
Kashimoto, Naoki
Hirano, Tatsuya
Shimabara, Rumiko
Kawakubo, Yohei
Sato, Masayuki
Yamashita, Junpei
Yazaki, Akira
Tamura, Koichi
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-5106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5106
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia
    Tatsuji Mino
    Hiroshi Ureshino
    Taichi Ueshima
    Naoki Kashimoto
    Tomonori Yamaguchi
    Kazuhito Naka
    Toshiya Inaba
    Tatsuo Ichinohe
    Investigational New Drugs, 2023, 41 : 751 - 760
  • [2] A novel anticancer quinolone, (R)-WAC-224, has anti-leukemia activities against acute myeloid leukemia
    Mino, Tatsuji
    Ureshino, Hiroshi
    Ueshima, Taichi
    Kashimoto, Naoki
    Yamaguchi, Tomonori
    Naka, Kazuhito
    Inaba, Toshiya
    Ichinohe, Tatsuo
    INVESTIGATIONAL NEW DRUGS, 2023, 41 (05) : 751 - 760
  • [3] A Novel Anticancer Quinolone, ( R)-Wac-224 Monotherapy or Combination with Cytarabine/Venetoclax Confers Promising Activities Against Acute Myeloid Leukemia
    Mino, Tatsuji
    Ureshino, Hiroshi
    Ueshima, Taichi
    Kashimoto, Naoki
    Yamaguchi, Tomonori
    Takashima, Miyuki
    Sanuki, Yusuke
    Naka, Kazuhito
    Inaba, Toshiya
    Ichinohe, Tatsuo
    BLOOD, 2023, 142
  • [4] Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II
    C.M. Nijenhuis
    L. Lucas
    H. Rosing
    A.D.R. Huitema
    M. Mergui-Roelvink
    G. C. Jamieson
    J.A. Fox
    D.R. Mould
    J.H.M. Schellens
    J.H. Beijnen
    Investigational New Drugs, 2017, 35 : 478 - 490
  • [5] Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II
    Nijenhuis, C. M.
    Lucas, L.
    Rosing, H.
    Huitema, A. D. R.
    Mergui-Roelvink, M.
    Jamieson, G. C.
    Fox, J. A.
    Mould, D. R.
    Schellens, J. H. M.
    Beijnen, J. H.
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (04) : 478 - 490
  • [6] In Vivo and In Vitro Pharmacokinetic Studies of a Dual Topoisomerase I/II Inhibitor
    Hildebrandt, Jonas
    Bauerschlag, Dirk O.
    Fricker, Gert
    Girreser, Ulrich
    Konukiewitz, Bjoern
    Kellers, Franziska
    Maass, Nicolai
    Clement, Bernd
    Floerkemeier, Inken
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2025,
  • [7] Design and development of a new class of topoisomerase inhibitor: Preliminary in vivo evaluation in experimental colon cancer.
    Mincher, DJ
    Turnbull, A
    Bibby, MC
    Double, JA
    Gilmour, PS
    Lowe, G
    BRITISH JOURNAL OF CANCER, 1999, 80 : 50 - 50
  • [8] In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II
    Mistry, P
    Stewart, AJ
    Dangerfield, W
    Baker, M
    Liddle, C
    Bootle, D
    Kofler, B
    Laurie, D
    Denny, WA
    Baguley, B
    Charlton, PA
    ANTI-CANCER DRUGS, 2002, 13 (01) : 15 - 28
  • [9] Maleimide is a potent inhibitor of topoisomerase II in vitro and in vivo: A new mode of catalytic inhibition
    Jensen, LH
    Renodon-Corniere, A
    Wessel, I
    Langer, SW
    Sokilde, B
    Carstensen, EV
    Sehested, M
    Jensen, PB
    MOLECULAR PHARMACOLOGY, 2002, 61 (05) : 1235 - 1243
  • [10] In vitro and in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy
    Serikawa, Takehiro
    Kikuchi, Akira
    Sugaya, Susumu
    Suzuki, Norio
    Kikuchi, Hiroshi
    Tanaka, Kenichi
    JOURNAL OF CONTROLLED RELEASE, 2006, 113 (03) : 255 - 260
12345